Pay in 4 interest-free payments of $6.27 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
Phase 3 data with longer follow-up will clarify the long-term glycemic profile
Conclusion GLP-1 RAs show promise as a disease-modifying therapy for IIH, with potential benefits beyond weight loss
The translation of these results into real-world human benefit remains purely theoretical
(2023) 9:eadh0980
Th22 cells, producing IL-22, are elevated in HT and correlate with anti-thyroglobulin titers, suggesting a role in persistent inflammation (Deertekin et al
US$ 22.85
:max_bytes(150000):strip_icc()/GettyImages-1299286851-18ab6e02931940ad963dda93851b6dc7.jpg)
US$ 20.63
US$ 23.73
US$ 24.10
US$ 20.73
US$ 24.84
